At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 52 enrolled
Drug / intervention
Faster-acting insulin aspart +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes
In Brief
A Phase 1 clinical trial evaluating Faster-acting insulin aspart and insulin aspart for Diabetes and Diabetes Mellitus, Type 1. Completed, enrolled 52 participants across 1 site.
Detailed Summary
This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic properties (the effect of the investigated drug on the body) of NN1218 in subjects with type 1 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 1
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2012
First PostedJun 2012
Primary CompletionSep 2012
TodayJul 2026
First PostedJun 13, 2012
Enrollment StartJun 11, 2012
Primary CompletionSep 7, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 14.1 years ago
Interventions
Faster-acting insulin aspartdrug
A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
insulin aspartdrug
A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.